This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kindred Launches Hostile Tender Offer for Gentiva

NEW YORK (The Deal) -- Kindred Healthcare (KND - Get Report) is having another go at acquiring its reluctant target, Gentiva Health Services (GTIV), by launching an all-cash tender offer to acquire all outstanding shares of the company's common stock for $14.50 per share.

Kindred, the largest post-acute care health services provider in the U.S., announced its renewed interest Monday after the market close.

The new bid is an all-cash offer for a total equity value of about $573 million, which comes to $1.7 billion when Gentiva's debt is added in. If Gentiva refuses, Kindred said it "intends to amend the offer to seek to purchase 14.9% of Gentiva's outstanding shares," thus overcoming Gentiva's poison pill by becoming its largest shareholder.

The 14.9% share purchase would cost Kindred about $80 million, according to an SEC filing.

Gentiva, of Atanta, is the nation's largest provider of home health and hospice services. Together, the two companies could create a comprehensive platform to develop the value- and risk-based service models that experts believe the Affordable Care Act will require.

That's why Louisville-based Kindred is champing at the bit to get control of the company. "We remain confident that uniting our two highly complementary businesses would create a unique platform for coordinated patient care and deliver compelling clinical, strategic and financial benefits for all stakeholders," Kindred chairman and CEO Paul Diaz said in a Monday conference call with investors.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GTIV $19.19 -1.18%
KND $13.01 0.00%
MS $33.78 0.00%
AAPL $117.81 0.00%
FB $105.45 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs